- Home
- BIIB vs RF Comparison
BIIB vs RF Comparison
Compare BIIB & RF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BIIB | RF |
|---|---|---|
| Founded | 1978 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2B | 21.5B |
| IPO Year | 1991 | N/A |
Fundamental Metrics
Financial Performance| Metric | BIIB | RF |
|---|---|---|
| Price | $174.82 | $27.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 14 |
| Target Price | ★ $177.40 | $27.64 |
| AVG Volume (30 Days) | 2.7M | ★ 11.2M |
| Earning Date | 02-11-2026 | 01-16-2026 |
| Dividend Yield | N/A | ★ 3.81% |
| EPS Growth | N/A | ★ 27.93 |
| EPS | ★ 10.97 | 2.27 |
| Revenue | ★ $10,065,900,000.00 | $6,945,000,000.00 |
| Revenue This Year | $3.58 | $18.34 |
| Revenue Next Year | N/A | $4.34 |
| P/E Ratio | $15.92 | ★ $12.26 |
| Revenue Growth | 4.77 | ★ 5.90 |
| 52 Week Low | $110.04 | $17.74 |
| 52 Week High | $185.17 | $27.98 |
Technical Indicators
Market Signals| Indicator | BIIB | RF |
|---|---|---|
| Relative Strength Index (RSI) | 54.83 | 67.86 |
| Support Level | $168.56 | $27.29 |
| Resistance Level | $177.29 | $27.98 |
| Average True Range (ATR) | 4.93 | 0.48 |
| MACD | -1.31 | 0.05 |
| Stochastic Oscillator | 42.44 | 80.16 |
Price Performance
Historical ComparisonAbout BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
About RF Regions Financial Corporation
Regions Financial is a regional bank based in Alabama, with branches primarily in the Southeastern and Midwestern United States. Regions primarily provides traditional commercial and retail banking and also offers mortgage services, asset management, wealth management, securities brokerage, and trust services.